newsfilter
← Earnings
Earnings Releases·

Lexeo Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash, cash equivalents, and investments in marketable securities totaled $219.1 million as of September 30, 2026, providing an operational runway into 2028.
    • Research and development expenses were $34.5 million for the three months ended September 30, 2026, compared to $15.7 million in the same period of 2025.
    • General and administrative expenses were $5.9 million for the three months ended September 30, 2026, compared to $6.0 million in the same period of 2025.
    • Net loss was $38.3 million ($0.43 per share, basic and diluted) for the three months ended September 30, 2026, compared to $20.3 million ($0.33 per share) in the same period of 2025.
    • Total operating expenses for the nine months ended September 30, 2026, were $90.8 million, compared to $86.1 million in the prior year period.
    • Net loss for the nine months ended September 30, 2026, was $84.4 million ($0.99 per share), compared to $79.0 million ($1.72 per share) in the prior year period.
    • Interest income was $2.2 million for the three months ended September 30, 2026, compared to $1.5 million in the prior year period.
  • Guidance and Future Outlook:

    • Lexeo expects to finalize the pivotal study design, statistical analysis plan, and confirmatory strategy in the first half of 2027.
    • The company expects to initiate a pivotal study supporting accelerated approval in the second half of 2027.
    • The FDA has indicated openness to using guideline-defined non-sustained ventricular tachycardia (NSVT) as a primary surrogate endpoint to support potential accelerated approval of LX2020.
  • Business Segments and Product Lines:

    • Interim Phase I/II data for LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) showed an 80% mean reduction in NSVT and a 44% mean reduction in premature ventricular contractions (PVC) in high-dose cohorts.
    • Five of seven participants in high-dose cohorts reported symptom improvement on the Patient Global Impression of Change (PGIC) scale.
    • Preliminary evidence indicates stabilization or improvement in cardiac function assessed by cardiac MRI in the majority of high-dose participants.
    • Clinical biopsy findings demonstrated dose-dependent increases in LX2020 transduction and PKP2 protein expression.
    • The acquisition of Mantle Therapeutics closed in September 2026, contributing to increased R&D expenses.
    • A development milestone related to the LX2006 pivotal study initiation was achieved in the third quarter of 2026.
  • Market and Competitive Landscape:

    • PKP2 mutations are the most common genetic cause of ACM, affecting approximately 60,000 people in the United States.
    • Management stated that the magnitude and consistency of NSVT reduction with LX2020 far exceed what available therapies have historically achieved.
  • Risks and Challenges:

    • Elevations in liver function tests (LFT) were observed in high-dose cohorts but were treated successfully with no complications or hospitalizations.
    • One Grade 3 serious adverse event of ventricular tachycardia (VT) occurred three months after dosing; this event is consistent with the natural course of PKP2-ACM and was successfully treated.
    • Final study design and confirmatory strategy remain subject to future discussions with the FDA.
  • Management Commentary and Tone:

    • CEO R. Nolan Townsend expressed strengthened confidence in LX2020, noting its potential to address the underlying biology of PKP2-ACM and improve patient outcomes.
    • The company highlighted that regulatory discussions have provided clarity on the path forward regarding the use of NSVT as a primary endpoint.
  • Other Key Points:

    • The company announced the appointment of Toby Schilke as an independent director to the Board of Directors; he previously served as CFO of Crinetics Pharmaceuticals, Revance Therapeutics, and Achaogen.
    • LX2020 has received Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations from the FDA.
    • The HEROIC-PKP2 Phase I/II trial included ten participants, with nine reaching at least 12 months of follow-up as of October 15, 2026.
    • No clinically significant complement activation was observed, and no participants discontinued the study.
Company
LEXEO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology